Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

46results about How to "Easy for industrial automation production" patented technology

Glucagon-like peptide 1 (GLP-1) analogues with long-acting effect and application thereof

The invention relates to glucagon-like peptide 1 (GLP-1) analogues with a long-acting effect and a synthesis method thereof. GLP-1 analogues with longer pharmacological action time are obtained through replacing / modifying 17th, 26th, 34th and 37th amino acids of natural GLP-1, the synthesis of target polypeptides is quickly realized through a microwave-promoted solid-phase synthesis method, and crude products are purified and freeze-dried to obtain the GLP-1 analogues.
Owner:CHINA PHARM UNIV

Novel long-acting glucagon-like peptide 1 (GLP-1) analogues and application thereof

The invention relates to novel long-acting glucagon-like peptide 1 (GLP-1) analogues and a synthesis method thereof. GLP-1 analogues with longer pharmacological action time are obtained through replacing / modifying 17th, 26th, 34th and 37th amino acids of natural GLP-1, the synthesis of target polypeptides is quickly realized through a microwave-promoted solid-phase synthesis method, and crude products are purified and freeze-dried to the GLP-1 analogues.
Owner:CHINA PHARM UNIV

Design and application of novel long acting hypoglycemic peptide

The invention relates to design and synthetic method of novel long acting hypoglycemic peptide. An Exending-4 derivative with longer pharmacological action time is obtained through the transformation on Exending-4, synthesis of target polypeptide is rapidly realized through an orthogonally protect strategy solid-phase synthesis method, and a crude product is subjected to purification and freeze-drying, so that the long acting hypoglycemic peptide is obtained.
Owner:CHINA PHARM UNIV

Novel peptide conjugate of African clawed frog GLP-1 (glucagon like peptide-1), as well as application thereof

The invention relates to a novel peptide conjugate of African clawed frog GLP-1 (glucagon like peptide-1), as well as a synthesis method and application thereof. A spiral promoting sequence is introduced to a terminal C of the African clawed frog GLP-1, and meanwhile, PEG (polyethylene glycol)-based modification is performed to obtain an analogue, with reserved hypoglycemic activity and longer pharmacological action time, of the African clawed frog GLP-1. The analogue of the African clawed frog GLP-1 has the advantages of high synthesis yield and low cost, the half-life of the analogue is remarkably prolonged, and the bioactivity is remarkably improved.
Owner:XUZHOU NORMAL UNIVERSITY

Long-acting Exenatide Derivatives and Salts, Preparation Methods and Applications

The invention is a long-acting exenatide derivative, which belongs to the technical field of polypeptide compounds. The exenatide derivative is structurally optimized for the exenatide sequence, so that it has hypoglycemic and weight-reducing effects at the same time, and double the amount of exenatide is conjugated with a single amount of fatty acid chains. The fatty acid chain plays a binding role with serum albumin to obtain exenatide derivatives with longer pharmacological action time. The invention also discloses a preparation method of exenatide derivatives, a pharmaceutically acceptable salt of exenatide derivatives, a pharmaceutical composition of exenatide derivatives, a pharmaceutical composition and a use thereof. Application of the derivative in the preparation of medicines for treating and / or preventing diabetes, obesity, hyperlipidemia and non-alcoholic fatty liver. The long-acting exenatide derivatives can reduce the weight on the basis of retaining the hypoglycemic activity, and the biological half-life is significantly longer than that of the exenatide prototype, and some of them have reached more than 36 hours, which greatly prolongs the hypoglycemic effect. Time of bariatric action.
Owner:SINOPEP ALLSINO BIOPHARMACEUTICAL CO LTD +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products